Abeona Therapeutics (NASDAQ:ABEO) Downgraded by StockNews.com to “Sell”

Abeona Therapeutics (NASDAQ:ABEO) was downgraded by research analysts at StockNews.com from a “hold” rating to a “sell” rating in a research report issued to clients and investors on Thursday.

Several other brokerages have also commented on ABEO. HC Wainwright reaffirmed a “buy” rating and issued a $15.00 price objective on shares of Abeona Therapeutics in a report on Monday, November 25th. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $18.00 price objective on shares of Abeona Therapeutics in a report on Tuesday, October 29th.

Abeona Therapeutics Stock Performance

Shares of ABEO opened at $5.89 on Thursday. The company has a debt-to-equity ratio of 0.31, a current ratio of 6.12 and a quick ratio of 6.12. Abeona Therapeutics has a one year low of $3.05 and a one year high of $9.01. The firm has a market capitalization of $256.04 million, a P/E ratio of -2.19 and a beta of 1.44. The business has a fifty day moving average of $6.24 and a 200 day moving average of $5.46.

Institutional Trading of Abeona Therapeutics

Several hedge funds have recently bought and sold shares of the stock. Jane Street Group LLC purchased a new position in shares of Abeona Therapeutics in the third quarter valued at about $84,000. Charles Schwab Investment Management Inc. purchased a new position in shares of Abeona Therapeutics in the third quarter valued at about $151,000. XTX Topco Ltd purchased a new position in shares of Abeona Therapeutics in the third quarter valued at about $160,000. Bank of New York Mellon Corp lifted its position in shares of Abeona Therapeutics by 2.0% in the second quarter. Bank of New York Mellon Corp now owns 121,453 shares of the biopharmaceutical company’s stock valued at $515,000 after acquiring an additional 2,434 shares in the last quarter. Finally, GSA Capital Partners LLP lifted its position in shares of Abeona Therapeutics by 54.3% in the third quarter. GSA Capital Partners LLP now owns 96,092 shares of the biopharmaceutical company’s stock valued at $607,000 after acquiring an additional 33,831 shares in the last quarter. Institutional investors own 80.56% of the company’s stock.

Abeona Therapeutics Company Profile

Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.